Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: ChAdOx1-MVA 5T4 Vaccine and Nivolumab in Prostate Cancer
NCT03815942Phase 2Terminated
- Sponsor
- University of Oxford
- Start
- Dec 2018
- Primary completion
- Jun 2020
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of ChAdOx1-MVA 5T4 vaccine in prostate cancer (PCa) (2 arms), sponsored by University of Oxford. Primary endpoints: Incidence of Treatment-related Adverse Events at 12 months and Composite Response Rate (ctDNA and PSA) at 12 months. Started Dec 2018; status: terminated.
02
Drugs
ChAdOx1-MVA 5T4 vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03815942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815942.